Five high-value biotech stocks to watch

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value plays in the months ahead. One reason Simeonidis is focusing on value, he explains, is that there are fewer catalyst-driven stories looming in his universe, "while I find myself speaking to investors more about value, especially given the uncertainty of the markets." In the mood for some market risk...

Burrill: Biopharma no longer a shelter in the storm

Once upon a time, says biotech handicapper and investor G. Steven Burrill, biopharma stocks offered shelter during a market storm. Now, they're getting doused along with everybody else. "At one time, in periods of economic uncertainty, investors would move into the relative safety of biotech and pharma," said the high-profile Burrill, CEO of Burrill & Company. "However, this is no longer the case and for the foreseeable future biotech's fortunes will be linked with the performance of the...

GenVec gets another NASDAQ warning

Gaithersburg, MD-based GenVec (NASDAQ: GNVC) has been informed that its stock price no longer meets NASDAQ requirements and could be delisted. The Washington Business Journal reports that GenVec stock, trading around 62 cents per share, has been below the minimum requirement of $1 per share for more than 30 consecutive business days. A notification letter from the NASDAQ exchange says GenVec has until Nov. 8 to regain compliance with the minimum closing bid price requirement. To...

Is the market for biotech start-ups coming back to life?

It's spring, and there's renewed hope in the deal-making community that for a select few venture-backed companies IPOs and buyouts are coming back into fashion. VentureSource tracked 15 VC-funded companies that changed hands last week, leading the Wall Street Journal to conclude that some big companies are getting back in the M&A game while the IPO market is showing distinct signs of life. Could this be some sort of sign that the old go-go market is back? No, says Venrock's Bryan...